Biofil Chemicals and Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
Biofil Chemicals and Pharmaceuticals's earnings have been declining at an average annual rate of -16.9%, while the Pharmaceuticals industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 4.2% per year. Biofil Chemicals and Pharmaceuticals's return on equity is 3.5%, and it has net margins of 1.4%.
Key information
-16.9%
Earnings growth rate
-17.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 4.2% |
| Return on equity | 3.5% |
| Net Margin | 1.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Biofil Chemicals and Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 460 | 6 | 6 | 0 |
| 31 Mar 24 | 404 | 7 | 7 | 0 |
| 31 Dec 23 | 384 | 7 | 7 | 0 |
| 30 Sep 23 | 349 | 7 | 7 | 0 |
| 30 Jun 23 | 202 | 6 | 10 | 0 |
| 31 Mar 23 | 300 | 6 | 6 | 0 |
| 31 Dec 22 | 181 | 3 | 7 | 0 |
| 30 Sep 22 | 182 | 6 | 7 | 0 |
| 30 Jun 22 | 293 | 7 | 11 | 0 |
| 31 Mar 22 | 224 | 7 | 8 | 0 |
| 31 Dec 21 | 354 | 3 | 7 | 0 |
| 30 Sep 21 | 370 | 5 | 7 | 0 |
| 30 Jun 21 | 396 | 12 | 8 | 0 |
| 31 Mar 21 | 358 | 12 | 8 | 0 |
| 31 Dec 20 | 260 | 18 | 8 | 0 |
| 30 Sep 20 | 356 | 15 | 9 | 0 |
| 30 Jun 20 | 312 | 14 | 8 | 0 |
| 31 Mar 20 | 298 | 12 | 9 | 0 |
| 31 Dec 19 | 286 | 11 | 10 | 0 |
| 30 Sep 19 | 300 | 11 | 9 | 0 |
| 30 Jun 19 | 205 | 5 | 9 | 0 |
| 31 Mar 19 | 232 | 5 | 9 | 0 |
| 31 Dec 18 | 242 | 5 | 9 | 0 |
| 30 Sep 18 | 108 | 5 | 9 | 0 |
| 30 Jun 18 | 95 | 4 | 9 | 0 |
| 31 Mar 18 | 124 | 5 | 7 | 0 |
| 31 Dec 17 | 151 | 14 | 15 | 0 |
| 30 Sep 17 | 181 | 17 | 15 | 0 |
| 30 Jun 17 | 202 | 19 | 5 | 0 |
| 31 Mar 17 | 135 | 18 | 5 | 0 |
| 31 Dec 16 | 122 | 13 | 10 | 0 |
| 30 Sep 16 | 152 | 9 | 10 | 0 |
| 30 Jun 16 | 130 | 8 | 5 | 0 |
| 31 Mar 16 | 132 | 8 | 9 | 0 |
| 31 Dec 15 | 119 | 6 | 7 | 0 |
| 30 Sep 15 | 59 | 5 | 7 | 0 |
| 30 Jun 15 | 61 | 6 | 7 | 0 |
| 31 Mar 15 | 59 | 6 | 7 | 0 |
| 31 Dec 14 | 68 | 6 | 10 | 0 |
| 30 Sep 14 | 66 | 6 | 9 | 0 |
| 30 Jun 14 | 68 | 5 | 4 | 0 |
| 31 Mar 14 | 72 | 5 | 9 | 0 |
| 31 Dec 13 | 71 | 9 | 8 | 0 |
| 30 Sep 13 | 43 | 5 | 5 | 0 |
Quality Earnings: 524396 has high quality earnings.
Growing Profit Margin: 524396's current net profit margins (1.4%) are lower than last year (3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524396's earnings have declined by 16.9% per year over the past 5 years.
Accelerating Growth: 524396's earnings growth over the past year (6%) exceeds its 5-year average (-16.9% per year).
Earnings vs Industry: 524396 earnings growth over the past year (6%) did not outperform the Pharmaceuticals industry 19.2%.
Return on Equity
High ROE: 524396's Return on Equity (3.5%) is considered low.